This company is no longer active
InDex Pharmaceuticals Holding Future Growth
Future criteria checks 0/6
InDex Pharmaceuticals Holding's earnings are forecast to decline at 48.5% per annum. EPS is expected to decline by 47.7% per annum.
Key information
-48.5%
Earnings growth rate
-47.7%
EPS growth rate
Pharmaceuticals earnings growth | 75.4% |
Revenue growth rate | n/a |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 10 Jun 2024 |
Recent future growth updates
Recent updates
Market Might Still Lack Some Conviction On InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Even After 35% Share Price Boost
Jun 13Further Upside For InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Shares Could Introduce Price Risks After 26% Bounce
Apr 28We're Keeping An Eye On InDex Pharmaceuticals Holding's (STO:INDEX) Cash Burn Rate
Jul 11We Think InDex Pharmaceuticals Holding (STO:INDEX) Can Afford To Drive Business Growth
Jan 21We Think InDex Pharmaceuticals Holding (STO:INDEX) Can Afford To Drive Business Growth
Aug 31Here's Why We're Watching InDex Pharmaceuticals Holding's (STO:INDEX) Cash Burn Situation
Mar 29InDex Pharmaceuticals Holding's (STO:INDEX) Shareholders Are Down 24% On Their Investment Over The Past Year.
Feb 04How Much Are InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Insiders Spending On Buying Shares?
Dec 21Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
3/31/2024 | 108 | -56 | -49 | -49 | N/A |
12/31/2023 | 98 | -95 | -38 | -38 | N/A |
9/30/2023 | 98 | -46 | -25 | -25 | N/A |
6/30/2023 | 98 | -12 | -1 | -1 | N/A |
3/31/2023 | 1 | -123 | -134 | -134 | N/A |
12/31/2022 | 1 | -100 | -129 | -129 | N/A |
9/30/2022 | -2 | -67 | -139 | -139 | N/A |
6/30/2022 | -2 | -92 | -142 | -142 | N/A |
3/31/2022 | 0 | -113 | -134 | -134 | N/A |
12/31/2021 | 0 | -103 | -124 | -124 | N/A |
9/30/2021 | 3 | -90 | -88 | -88 | N/A |
6/30/2021 | 3 | -70 | -66 | -70 | N/A |
3/31/2021 | 0 | -43 | -58 | -57 | N/A |
12/31/2020 | 0 | -57 | -72 | -71 | N/A |
9/30/2020 | 0 | -73 | -98 | -97 | N/A |
6/30/2020 | 0 | -92 | -112 | -108 | N/A |
3/31/2020 | 0 | -95 | -89 | -89 | N/A |
12/31/2019 | 0 | -88 | -85 | -85 | N/A |
9/30/2019 | 0 | -84 | -71 | -71 | N/A |
6/30/2019 | 0 | -72 | -68 | -68 | N/A |
3/31/2019 | 0 | -81 | -74 | -74 | N/A |
12/31/2018 | 1 | -82 | -79 | -79 | N/A |
9/30/2018 | 0 | -82 | -73 | -73 | N/A |
6/30/2018 | 0 | -80 | -73 | -73 | N/A |
3/31/2018 | 0 | -69 | -72 | -72 | N/A |
12/31/2017 | 0 | -73 | N/A | -67 | N/A |
9/30/2017 | 0 | -67 | N/A | -83 | N/A |
6/30/2017 | 0 | -61 | N/A | -74 | N/A |
3/31/2017 | 0 | -56 | N/A | -64 | N/A |
12/31/2016 | 0 | -41 | N/A | -32 | N/A |
9/30/2016 | 0 | -31 | N/A | -11 | N/A |
6/30/2016 | 0 | -31 | N/A | -11 | N/A |
3/31/2016 | 0 | -29 | N/A | -14 | N/A |
12/31/2015 | 0 | -30 | N/A | -37 | N/A |
9/30/2015 | 0 | -33 | N/A | -42 | N/A |
6/30/2015 | 0 | -36 | N/A | -46 | N/A |
3/31/2015 | 23 | -25 | N/A | -27 | N/A |
12/31/2014 | 45 | -15 | N/A | -8 | N/A |
12/31/2013 | 1 | -68 | N/A | -116 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: INDEX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: INDEX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: INDEX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if INDEX's revenue is forecast to grow faster than the Swedish market.
High Growth Revenue: Insufficient data to determine if INDEX's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if INDEX's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/06/10 09:53 |
End of Day Share Price | 2024/06/10 00:00 |
Earnings | 2024/03/31 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
InDex Pharmaceuticals Holding AB (publ) is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Arvid Necander | Carnegie Investment Bank AB |
Filip Einarsson | Redeye |